Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
Follicular Lymphoma
Conditions: official terms
Lymphoma, Follicular
Conditions: Keywords
radioimmunotherapy, follicular non-Hodgkin´s lymphoma, FDG-PET, prognostic factors, multicenter study
Study Type
Study Phase
Study Design
Time Perspective: Prospective
Overall Status
MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive.

Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in treatment of relapsed and/or refractory follicular NHL or partial remission after induction chemotherapy

- finding of at least one image-guided measurable lymphoma lesion

- existence of FDG-PET- and CT-image data of at most 8 weeks before treatment

- signed patient´s agreement for RIT registry and MERIT-NHL

Exclusion Criteria:

- other therapy modalities than standard radioimmunotherapy (e.g. consolidation)

- solely CNS-lymphoma or primary effusion lymphoma
Dept. of Nuclear Medicine, Saarland University Hospital
Homburg (Saar), Saarland, Germany
Status: Recruiting
Contact: Aleksandar Grgic, MD - +49-6841-16-22201 - merit@uks.eu
Klinikum Karlsruhe, Dept. of Nuclear Medicine
Karlsruhe, Germany
Status: Recruiting
Contact: Cornelia Puskas, MD
University Clinic Kiel-Luebeck
Luebeck, Germany
Status: Active, not recruiting
Technical University, Dept. of Nuclear Medicine
Munich, Germany
Status: Recruiting
Contact: Klemens Scheidhauer, MD
Start Date
May 2008
Completion Date
December 2011
University Hospital, Saarland
University Hospital, Saarland
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page